Inflammatory Myopathies: Evaluation and Management

Seminars in Neurology

Volumn 28, Issue 2, 2008, Pages 241-249

  Greenberg, Steven A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myopathy; Necrotizing myopathy; Polymyositis

Indexed keywords

ALENDRONIC ACID; ANTIPRURITIC AGENT; AZATHIOPRINE; BETA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLOROQUINE; CORTICOSTEROID; GLUCOCORTICOID; IBANDRONIC ACID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PAMIDRONIC ACID; PREDNISONE; RISEDRONIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY; VITAMIN D; ZOLEDRONIC ACID;

ALOPECIA; ANEMIA; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; INFECTION RISK; KIDNEY DISEASE; LIVER DISEASE; LOW DRUG DOSE; MYOSITIS; OSTEOPOROSIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; STOMATITIS; UNSPECIFIED SIDE EFFECT;

AUTOIMMUNE DISEASES; CHEMOTAXIS, LEUKOCYTE; DERMATOMYOSITIS; HUMANS; IMMUNOLOGIC FACTORS; MUSCLE FIBERS; MUSCLE, SKELETAL; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 41149160432     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1062267     Document Type: Review

References (48)

1. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and their potential therapeutic implications. Neurology 2007;69:2008-2019
2. Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol 2004;29:273-276
3. Hundley JL, Carroll CL, Lang W, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006;54:217-220
4. Kubis N, Woimant F, Polivka M, et al. A case of dermatomyositis and muscle sarcoidosis in a Caucasian patient. J Neurol 1998;245:50-52
5. Hart Y, Schwartz MS, Bruckner F, McKeran RO. Relapsing dermatomyositis associated with sarcoidosis. J Neurol Neurosurg Psychiatry 1988;51:311-313
6. Lipton JH, McLeod BD, Brownell AK. Dermatomyositis and granulomatous myopathy associated with sarcoidosis. Can J Neurol Sci 1988;15:426-429
7. Brateanu AC, Caracioni A, Smith HR. Sarcoidosis and dermatomyositis in a patient with hemoglobin SC. A case report and literature review. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:190-193
8. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-678
9. Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971;25:240-248
10. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989;112(Pt 3):727-747
11. Badrising UA, Maat-Schieman ML, van Houwelingen JCet al.. Inclusion body myositis Clinical features and clinical course of the disease in 64 patients. J Neurol 2005;252(12):1448-1454
12. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000;55:1385-1387
13. Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 1993;71:351-361
14. Lindberg C, Persson LI, Bjorkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994;89:123-131
15. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992;19:1385-1389
16. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-713
17. van der Meulen MF, Hoogendijk JE, Moons KG, et al. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord 2001;11:447-451
18. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-345
19. Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003;61:288-289
20. van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-321
21. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347
22. Miller FW, Rider LG, Plotz PH, et al. Diagnostic criteria for polymyositis and dermatomyositis. Lancet 2003;362:1762-1763 author reply 1763
23. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-982
24. Krahn M, Lopez de Munain A, Streichenberger N, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006;59:905-911
25. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991;41:936-939
26. De Bleecker J, Vervaet V, Van den Bergh P. Necrotizing myopathy with microvascular deposition of the complement membrane attack complex. Clin Neuropathol 2004;23:76-79
27. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998;50:764-767
28. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002;218:74-86
29. Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003;250:480-485
30. Dimitri D, Andre C, Roucoules J, et al. Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007;35:389-395
31. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635-1638
32. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body The MSG myositis. Neurology 2004;63:718-720
33. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57:1566-1570
34. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-716
35. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327
36. Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51:369-372
37. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-28
38. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003;61:260-262
39. Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-511
40. Summey BT, Yosipovitch G. Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol 2006;142:82-90
41. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-299
42. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-285
43. Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006;66:1245-1247
44. Viguier M, Fouéré S, de la Salmonière P, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 2003;82:82-86
45. Uchino M, Araki S, Yoshida O, et al. High single-dose alternate-day corticosteroid regimens in treatment of polymyositis. J Neurol 1985;232:175-178
46. Fenichel GM, Mendell JR, Moxley RT III, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991;48:575-579
47. Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981;24:892-898
48. Miller FW, Leitman SF, Cronin M, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380-1384